Based on its recent analysis of the influenza vaccines market, Frost & Sullivan has recognized Protein Sciences of Meriden with the 2013 Global New Product Innovation Award.  Flublok® is the world’s first recombinant protein vaccine for the prevention of seasonal influenza disease to gain U.S. FDA approval.

Unlike influenza vaccines that contain a part of the whole flu virus, Flublok comprises purified recombinant hemagglutinin antigens (HA), which correspond to the HAs expressed on the surface of influenza viruses, but are made without growing live flu viruses. The vaccine is tailored annually to provide protection against the latest strains of influenza by containing the corresponding recombinant HAs for those strains.